How Ph.D. was paid
$2.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Mark A. Velleca, M.D., Ph.D.President and Chief Executive Officer | $667,400 | $189,000 | $1,006,030 | $348,717 | $23,772 | $2,234,919 |
| Brent Hatzis-Schoch, Esq.Chief Operating Officer and General Counsel | $511,000 | $189,000 | $352,029 | $206,444 | $23,772 | $1,282,245 |
| Sergey Yurasov, M.D., Ph.D.Chief Medical Officer | $525,600 | $189,000 | $402,348 | $212,342 | $22,806 | $1,352,097 |
What changed and why
- $2.2MCEO total compensation decreased to $2,234,919 in 2025 from $2,855,111 in 2024.
- 3.50%Base salaries for named executive officers increased by approximately 3.50% for 2025.
- 95%Corporate performance goals were achieved at 95% of target for the 2025 fiscal year.
- Restricted stock units and stock options were granted to align executives with long-term performance.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.